Collection of Biological Samples With Clinical Characterization of Covid-19 Patients

Centre Hospitalier Intercommunal Creteil

Status: Terminated

Conditions: Covid-19

Treatments: Biological: Biological test

Study type: Interventional

Funder types: Other

Identifiers

NCT04363385

COVIGENET

Details and patient eligibility

About

Biological collection (blood sample) associated with clinical data from Covid-19 patients

Full description

SARS-Cov2 is an emerging respiratory virus in the coronavirus family, responsible of the pandemic since November 2019. France, which has more than 17,000 deaths from the virus, is one of the main outbreaks. As of 16 April 2020, more than 76,000 individuals in France have been hospitalized, corresponding to 69% of confirmed cases (https://www.santepubliquefrance.fr).

Most affected patients have more or less marked clinical signs associating fever, cough, dyspnea, myalgia, anosmia, ageusia, digestive disorders. In some cases, the progression is worse with lung disease of varying severity. Indications for hospitalization are essentially the severe forms of Covid-19 disease, characterized by hypoxemic lung disease.

Risk factors for developing severe Covid-19 disease have been identified already: age, co-morbidity such as diabetes, obesity-overweight or cardiovascular diseases. It is assumed that other host-related factors, including genetics, may contribute to the existence of this phenotypic heterogeneity. At present, these factors are not known.

The objective of this research is to constitute a DNA collection from patients with Covid-19, in order to be able to search for genetic factors modulating the clinical phenotype.

Enrollment: 500 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of COVID-19 confirmed on RT-PCR test or chest scanner
• Any age
• Membership in the general social security system
• Inform consent signed by the patient or by legal representatives for minors

Exclusion criteria

• Refusal of the patient or one of the legal representatives

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

500 participants in 1 patient group

Collection of blood sample

Other group

Treatment:

Biological: Biological test